NBIX vs TRU · P/E 45, rev $1.77B vs P/E 19, rev $4.58B
Neurocrine Biosciences Inc (NBIX) versus TransUnion (TRU) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
TransUnion (TRU) is a financial data & stock exchanges company listed on NYSE.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported TRU revenue for 2025-12-31 was $4.58B. Net income was $455.4M. Revenue was up 9.4% from 2024-12-31 to 2025-12-31. TRU currently screens at market cap $13.41B and trailing P/E 19.3.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. TRU currently screens at market cap $13.41B and trailing P/E 19.3.
Not investment advice. Open the NBIX and TRU stock pages for the full models.
Not investment advice.